Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany

Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany

Knowledge on the real-world characteristics and outcomes of pembrolizumab-treated advanced melanoma patients in Germany and on the value of different real-world endpoints as surrogates for overall survival (OS) is limited. A sample of 664 pembrolizumab-treated patients with advanced melanoma from th...

Full description

Bibliographic Details
Main Authors: Peter Mohr, Emilie Scherrer, Chalid Assaf, Marc Bender, Carola Berking, Sheenu Chandwani, Thomas Eigentler, Imke Grimmelmann, Ralf Gutzmer, Sebastian Haferkamp, Jessica C. Hassel, Axel Hauschild, Rudolf Herbst, Ruixuan Jiang, Katharina C. Kähler, Clemens Krepler, Alexander Kreuter, Ulrike Leiter, Carmen Loquai, Friedegund Meier, Claudia Pföhler, Anja Rudolph, Dirk Schadendorf, Maximo Schiavone, Gaston Schley, Patrick Terheyden, Selma Ugurel, Jens Ulrich, Jochen Utikal, Carsten Weishaupt, Julia Welzel, Michael Weichenthal
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Cancers
Subjects:
advanced melanoma
surrogate endpoint
real-world evidence
overall survival (OS)
time to next treatment (rwTtNT)
pembrolizumab
Online Access:https://www.mdpi.com/2072-6694/14/7/1804

Internet

https://www.mdpi.com/2072-6694/14/7/1804

Similar Items